Anna van der Voort

829 total citations
17 papers, 481 citations indexed

About

Anna van der Voort is a scholar working on Oncology, Cancer Research and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Anna van der Voort has authored 17 papers receiving a total of 481 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 10 papers in Cancer Research and 6 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Anna van der Voort's work include Breast Cancer Treatment Studies (9 papers), HER2/EGFR in Cancer Research (9 papers) and Cancer Treatment and Pharmacology (6 papers). Anna van der Voort is often cited by papers focused on Breast Cancer Treatment Studies (9 papers), HER2/EGFR in Cancer Research (9 papers) and Cancer Treatment and Pharmacology (6 papers). Anna van der Voort collaborates with scholars based in Netherlands, Belgium and Italy. Anna van der Voort's co-authors include Gabe S. Sonke, Jelle Wesseling, Mette S. van Ramshorst, Erik van Werkhoven, M. Steinbuch, Ingrid A.M. Mandjes, René van de Molengraft, Agnès J. van de Wouw, Aafke H. Honkoop and Lidwine W. Tick and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and The Lancet Oncology.

In The Last Decade

Anna van der Voort

15 papers receiving 475 citations

Peers

Anna van der Voort
Panagiotis Paraskevopoulos Greece
Mei Jin China
Barbara M. Zonderhuis Netherlands
Zhiyuan Cai China
Wenjuan Zheng China
V. Van Belle Belgium
Sum-Fu Chiang Taiwan
Panagiotis Paraskevopoulos Greece
Anna van der Voort
Citations per year, relative to Anna van der Voort Anna van der Voort (= 1×) peers Panagiotis Paraskevopoulos

Countries citing papers authored by Anna van der Voort

Since Specialization
Citations

This map shows the geographic impact of Anna van der Voort's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anna van der Voort with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anna van der Voort more than expected).

Fields of papers citing papers by Anna van der Voort

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anna van der Voort. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anna van der Voort. The network helps show where Anna van der Voort may publish in the future.

Co-authorship network of co-authors of Anna van der Voort

This figure shows the co-authorship network connecting the top 25 collaborators of Anna van der Voort. A scholar is included among the top collaborators of Anna van der Voort based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anna van der Voort. Anna van der Voort is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Han, Luyi, Tianyu Zhang, Anna D’Angelo, et al.. (2025). Exploring personalized neoadjuvant therapy selection strategies in breast cancer: an explainable multi-modal response model. EClinicalMedicine. 86. 103356–103356.
2.
Voort, Anna van der, Ingrid A.M. Mandjes, Mariëtte J Agterof, et al.. (2025). Abstract RF1-03: Three-year event-free survival (EFS) of the multicenter phase II TRAIN-3 study evaluating image-guided optimization of neoadjuvant chemotherapy duration in stage II and III HER2-positive breast cancer (BOOG 2018-01). Clinical Cancer Research. 31(12_Supplement). RF1–3. 1 indexed citations
3.
Liefaard, Marte C., Anna van der Voort, Maartje van Seijen, et al.. (2024). Tumor-infiltrating lymphocytes in HER2-positive breast cancer treated with neoadjuvant chemotherapy and dual HER2-blockade. npj Breast Cancer. 10(1). 29–29. 10 indexed citations
4.
Voort, Anna van der, et al.. (2024). Diffusion-weighted imaging in addition to contrast-enhanced MRI in identifying complete response in HER2-positive breast cancer. European Radiology. 34(12). 7994–8004. 2 indexed citations
5.
Voort, Anna van der, C.P. Schröder, Astrid N. Scholten, et al.. (2024). 318TiP Neoadjuvant trastuzumab, pertuzumab and tucatinib without chemotherapy in stage II-III HER2-positive breast cancer: The TRAIN-4 study. Annals of Oncology. 35. S347–S347.
6.
Liefaard, Marte C., Anna van der Voort, Mette S. van Ramshorst, et al.. (2023). BluePrint molecular subtypes predict response to neoadjuvant pertuzumab in HER2-positive breast cancer. Breast Cancer Research. 25(1). 71–71. 3 indexed citations
7.
8.
Liefaard, Marte C., Rajith Bhaskaran, Anke Witteveen, et al.. (2022). 161P MammaPrint and BluePrint diagnostic tests can be robustly assessed on Whole-Transcriptome NGS platform. Annals of Oncology. 33. S612–S612. 1 indexed citations
9.
Voort, Anna van der, Natalia Govorukhina, Gabe S. Sonke, et al.. (2022). Biotransformation of Trastuzumab and Pertuzumab in Breast Cancer Patients Assessed by Affinity Enrichment and Ion-Exchange Chromatography. Drug Metabolism and Disposition. 51(2). 249–256. 2 indexed citations
10.
Liefaard, Marte C., Anna van der Voort, Maartje van Seijen, et al.. (2022). 145P Prognostic value of tumor-infiltrating lymphocytes in HER2-positive breast cancer treated with neoadjuvant chemotherapy and dual HER2-blockade: A TRAIN-2 sub study. Annals of Oncology. 33. S606–S606. 1 indexed citations
11.
Voort, Anna van der, Mette S. van Ramshorst, Erik van Werkhoven, et al.. (2021). Three-Year Follow-up of Neoadjuvant Chemotherapy With or Without Anthracyclines in the Presence of DualERBB2Blockade in Patients WithERBB2-Positive Breast Cancer. JAMA Oncology. 7(7). 978–978. 76 indexed citations
12.
Voort, Anna van der, Mette S. van Ramshorst, Erik van Werkhoven, et al.. (2020). Three-year follow-up of neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2-blockade for HER2-positive breast cancer (TRAIN-2): A randomized phase III trial.. Journal of Clinical Oncology. 38(15_suppl). 501–501. 24 indexed citations
13.
Veenhof, Herman, Job F. M. van Boven, Anna van der Voort, et al.. (2020). Effects, costs and implementation of monitoring kidney transplant patients' tacrolimus levels with dried blood spot sampling: A randomized controlled hybrid implementation trial. British Journal of Clinical Pharmacology. 86(7). 1357–1366. 26 indexed citations
14.
Voort, Anna van der, et al.. (2019). Abstract OT2-07-07: Image-guided de-escalation of neoadjuvant chemotherapy in HER2-positive breast cancer: The TRAIN-3 study. Cancer Research. 79(4_Supplement). OT2–7. 2 indexed citations
15.
Ramshorst, Mette S. van, Anna van der Voort, Erik van Werkhoven, et al.. (2018). Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial. The Lancet Oncology. 19(12). 1630–1640. 245 indexed citations
16.
Brandenbarg, Daan, et al.. (2017). Possible missed opportunities for diagnosing colorectal cancer in Dutch primary care: a multimethods approach. British Journal of General Practice. 68(666). e54–e62. 15 indexed citations
17.
Steinbuch, M., René van de Molengraft, & Anna van der Voort. (2004). Experimental modelling and LPV control of a motion system. 2. 1374–1379. 66 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Panagiotis Paraskevopoulos Breakdown of academic impact, for papers by Mei Jin Breakdown of academic impact, for papers by Barbara M. Zonderhuis Breakdown of academic impact, for papers by Zhiyuan Cai Breakdown of academic impact, for papers by Wenjuan Zheng Breakdown of academic impact, for papers by V. Van Belle Breakdown of academic impact, for papers by Sum-Fu Chiang
Rankless by CCL
2026